Lv11
40 积分 2024-01-04 加入
Splenic Size and Volume Measurements in Patients with Chronic Lymphocytic Leukemia
4小时前
求助中
Current and upcoming treatment approaches to common subtypes of PTCL (PTCL NOS, ALCL, TFHs)
2个月前
已完结
慢性鼻窦炎诊断和治疗指南（2024）
4个月前
已完结
Dermatological Toxicities of Bruton’s Tyrosine Kinase Inhibitors
4个月前
已完结
[Consensus on the clinical diagnosis, treatment, and prevention of cancer related anemia in China (2023 edition)]
4个月前
已完结
Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study
1年前
已完结
SHR2554, an EZH2 inhibitor, in relapsed or refractory mature lymphoid neoplasms: a first-in-human, dose-escalation, dose-expansion, and clinical expansion phase 1 trial
1年前
已完结
SHR2554, an EZH2 inhibitor, in relapsed or refractory mature lymphoid neoplasms: a first-in-human, dose-escalation, dose-expansion, and clinical expansion phase 1 trial
1年前
已完结
Relationship between response rates and median progression‐free survival in non‐Hodgkin's lymphoma: A meta‐analysis of published clinical trials
1年前
已完结
Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1–2 study
1年前
已完结
皖公网安备34019202002308
